ABT-199 (venetoclax) and BCL-2 inhibitors in clinical development

With the advent of new agents targeting CD20, Bruton's tyrosine kinase, and phosphoinositol-3 kinase for chronic lymphoid leukemia (CLL), more treatment options exist than ever before. B-cell lymphoma-2 (BCL-2) plays a major role in cellular apoptosis and is a druggable target. Small molecule i...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of hematology and oncology 2015-11, Vol.8 (129), p.129-129, Article 129
Hauptverfasser:	Cang, Shundong, Iragavarapu, Chaitanya, Savooji, John, Song, Yongping, Liu, Delong
Format:	Artikel
Sprache:	eng
Schlagworte:	Agammaglobulinaemia Tyrosine Kinase Antibodies Antigens Antimitotic agents Antineoplastic agents Antineoplastic Agents - pharmacology Antineoplastic Agents - therapeutic use Apoptosis Bridged Bicyclo Compounds, Heterocyclic - pharmacology Bridged Bicyclo Compounds, Heterocyclic - therapeutic use Cancer therapies Care and treatment Cell death Complications and side effects Cytochrome Health aspects Hematology Humans Immunotherapy Influence Kinases Leukemia Leukemia, Lymphoid - drug therapy Leukemia, Lymphoid - metabolism Lymphoma Melanoma Mitochondria Monoclonal antibodies Multiple myeloma Non-Hodgkin's lymphomas Oncology Phosphatidylinositol 3-Kinases - metabolism Protein-Tyrosine Kinases - drug effects Proteins Proto-Oncogene Proteins c-bcl-2 - antagonists & inhibitors Proto-Oncogene Proteins c-bcl-2 - metabolism Review Sulfonamides - pharmacology Sulfonamides - therapeutic use
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	With the advent of new agents targeting CD20, Bruton's tyrosine kinase, and phosphoinositol-3 kinase for chronic lymphoid leukemia (CLL), more treatment options exist than ever before. B-cell lymphoma-2 (BCL-2) plays a major role in cellular apoptosis and is a druggable target. Small molecule inhibitors of BCL-2 are in active clinical studies. ABT-199 (venetoclax, RG7601, GDC-0199) has been granted breakthrough designation by FDA for relapsed or refractory CLL with 17p deletion. In this review, we summarized the latest clinical development of ABT-199/venetoclax and other novel agents targeting the BCL-2 proteins.
ISSN:	1756-8722 1756-8722
DOI:	10.1186/s13045-015-0224-3